From information to follow‐up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting-Reference-Cited by-同舟云学术

From information to follow‐up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting

Published:2018-01 Issue:1 Volume:4 Page:243-251
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions

Author:

Vanderschaeghe Gwendolien¹,Schaeverbeke Jolien²³,Bruffaerts Rose²⁴,Vandenberghe Rik²³⁴,Dierickx Kris¹

Affiliation:

1. Centre for Biomedical Ethics and Law, Department of Public Health and Primary CareKU LeuvenLeuvenBelgium

2. Laboratory for Cognitive NeurologyDepartment of NeurosciencesKU LeuvenLeuvenBelgium

3. Alzheimer Research Centre KU Leuven, Leuven Research Institute for Neuroscience and Disease, KU LeuvenLeuvenBelgium

4. Neurology DepartmentUniversity Hospitals Leuven (UZ Leuven, Campus Gasthuisberg)Belgium

Publisher

Wiley

Subject

Psychiatry and Mental health,Clinical Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.trci.2018.04.002

Reference34 articles.

1. Disclosure of individual genetic data to research participants: the debate reconsidered

2. EMA.Why has Amyvid Been Approved?.2017 Available at:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002422/human_med_001611.jsp&mid=WC0b01ac058001d124 Accessed February 17 2017

3. European Medicines Agency.Vizamyl Marketing Authorisation Holder: GE HEALTHCARE LIMITED Assessment Report for an Initial Marketing Authorisation application.2014 Available at:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/002557/WC500172953.pdf. Accessed February 17 2017

4. Amyloid imaging, risk disclosure and Alzheimer’s disease: ethical and practical issues

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson’s Disease: A Narrative Review;Journal of Parkinson's Disease;2024-07-04

2. “And Does That Necessarily Mean Absolutely Alzheimer's?” An Analysis of Questions Raised Following Amyloid PET Results Disclosure;The American Journal of Geriatric Psychiatry;2024-01

3. Informing Alzheimer’s Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure;The Journal of Prevention of Alzheimer's Disease;2024

4. Informing Disclosure: Efficacy of a Brief Educational Intervention on Research Participants’ Knowledge about Alzheimer’s Disease Biomarkers;Journal of Alzheimer's Disease;2023-11-07

5. New Community and Sociohealth Challenges Arising from the Early Diagnosis of Mild Cognitive Impairment (MCI);Journal of Personalized Medicine;2023-09-20